| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Oramed Pharmaceuticals Inc. | Jan 10, 2025 | |
| Sell | Oramed Pharmaceuticals Inc. | Jan 14, 2022 | |
| Sell | Oramed Pharmaceuticals Inc. | Oct 1, 2021 | |
| Buy | Oramed Pharmaceuticals Inc. | Apr 23, 2021 |
This page tracks congressional stock trading activity in Oramed Pharmaceuticals Inc. (ORMP) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving ORMP. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of February 2025 — Disclosed Capitol has tracked 4 disclosed congressional trades in Oramed Pharmaceuticals Inc. (ORMP) — 3:1 sell-heavy ratio — led by Andrew Garbarino (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jan 10, 2025 | Brad Knott | R | Sell | $15,001 - $50,000 |
| Jan 14, 2022 | Andrew Garbarino | R | Sell | $1,001 - $15,000 |
| Oct 1, 2021 | Andrew Garbarino | R | Sell | $1,001 - $15,000 |
| Apr 23, 2021 | Andrew Garbarino | R | Buy | $1,001 - $15,000 |
Across the 4 disclosed congressional trades in Oramed Pharmaceuticals Inc. (ORMP), members of Congress have reported 1 buy and 3 sells. The average 30-day alpha vs. the S&P 500 is -0.11%.
As of October 2026, corporate insiders at Oramed Pharmaceuticals Inc. have filed 9 SEC Form 4 transactions in ORMP over the past 12 months — including 2 sells worth $226K.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-10-01 | Gabay Avraham — Chief Financial Officer | Sale | $90K |
| 2026-10-01 | Hexter Joshua — COO & CBO | Sale | $135K |
| 2026-09-24 | KIDRON NADAV — President and CEO | Award | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Award | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Disposition to Issuer | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Disposition to Issuer | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Disposition to Issuer | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Disposition to Issuer | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Disposition to Issuer | — |
| 2026-09-24 | KIDRON NADAV — President and CEO | Disposition to Issuer | — |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
For fiscal year 2025, Oramed Pharmaceuticals Inc. reported revenue of $2.0M and net income of $64.0M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $0, net income $13.3M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.